同期单药铂类化疗联合放疗治疗宫颈癌的效果观察  

Clinical efficacy of platinum-based chemotherapy combined radiotherapy for cervical cancer

作　　者：徐志渊[1] 林连兴[1] 颜明明[1] 

机构地区：[1]广东省汕头市中心医院放疗科,515000

出　　处：《中国综合临床》2012年第6期576-578,共3页Clinical Medicine of China

基　　金：汕头市重点科技计划项目（2009-70-24）

摘　　要：目的评价同期单药铂类化疗联合放疗治疗宫颈癌的临床疗效。方法2008年10月至2010年6月在我科治疗的宫颈癌患者61例，采用常规分割放射治疗及后装治疗，放疗总量8000～8500cGy。同期化疗采用奈达铂或顺铂20mg／m^2，每周1次，观察其近期疗效和毒副作用情况。结果61例患者近期有效率达100％（61／61），1年生存率达85．2％（52／61），其中奈达铂组为84．6％（22／26），顺铂组为85．7％（30／35），差异无统计学意义（Х^2=0．014，P=0．905）。毒副作用：顺铂组骨髓抑制Ⅰ度5例，Ⅱ度24例，Ⅲ度5例，Ⅳ度1例；奈达铂组0度2例，I度6例，Ⅱ度12例，Ⅲ度3例，Ⅳ度3例，差异无统计学意义（Х^2=6．402，P=0．171）。结论同期单药铂类化疗联合放疗治疗宫颈癌效果显著，且患者毒副反应轻。Objective To evaluate the clinical efficacy of platinum-based chemotherapy combined radiotherapy for cervical cancer. Methods From October 2008 to June 2010,61 patients with cervical cancer were treated by radiotherapy （conventional external radiation and after-loading bradhytherapy, to a total dose of 8000 - 8500 cGy） combined platinum-based chemotherapy （ cisplatin or nedaplatin 20 mg/m2, one times per weeks） in our department. The clinical efficacy and side effects were evaluated. Results Among 61 patients, the short-term effective rate was 100% （61/61） and 1-year survival rate was 85.2% （ 52/61 ）. There was no significant difference between cisplatin group and nedaplatin in 1-year survival rate （ 84. 6% vs. 85.7% , Х^2 = 0.014,P=0.095）. Arrest of bone marrow at Ⅰ , Ⅱ, Ⅲ and Ⅳlevel occurred 5,24,5 and 1 patients in the cisplatin group, and 6,12,3 and 3 patients in the nedaplatin group. There was also no significant difference between these two groups in great mass side effects induced by chemoradiotherapy（ X^2 = 6. 402,P = 0. 171 ）. Conclusion It is worth practising of platinum-based chemotherapy combined radiotherapy for cervical carcinoma. The side effects induced by chemoradiotherapy is low.

关 键 词：宫颈癌 放射疗法 化疗 奈达铂 顺铂 

分 类 号：R737.33[医药卫生—肿瘤]